8-K: Verastem's VS-7375 Shows Strong Efficacy in Pancreatic Cancer

Verastem Oncology announced positive updated safety and efficacy data from its partner GenFleet Therapeutics' Phase 1/2 monotherapy study of GFH375 (VS-7375) in advanced KRAS G12D mutant pancreatic cancer patients in China.

Summary

• Updated safety and efficacy data for GFH375 (VS-7375) from a Phase 1/2 monotherapy study in advanced KRAS G12D mutant pancreatic ductal adenocarcinoma (PDAC) patients in China were announced.
• The study included 66 patients with advanced KRAS G12D mutant PDAC, with 59 being heavily pre-treated (at least two prior lines of anticancer therapy).
• As of September 27, 2025, 59 efficacy-evaluable patients achieved an overall response rate (ORR) of 40.7% (24/59) and a disease control rate (DCR) of 96.7% (57/59) with 600 mg of VS-7375 monotherapy per day.
• 91.5% of patients experienced a reduction in target lesions.
• Overall Survival (OS) observed at month four was 92.2%; median OS was not reached as of the data cutoff, with a median follow-up time of 5.65 months.
• Median progression-free survival (PFS) was 5.52 months with a median follow-up time of 5.65 months, and a four-month PFS rate of 78.2%.
• 31 (47%) of patients were still on treatment, with the longest duration exceeding one year (367 days).
• The safety profile was consistent with previously reported data; Grade 3 TRAEs occurred in 20 patients (30.3%) and a Grade 4 TRAE (neutropenia) in one patient (1.5%).
• Only 3% (2 patients) discontinued due to treatment-related adverse events (TRAEs), and no TRAE-related deaths were reported.
• The mean relative dose intensity was 93%.

Sentiment

Score: 9

Explanation: The filing presents highly positive clinical data for VS-7375 in a challenging and unmet medical need area (advanced KRAS G12D mutant PDAC). The strong efficacy metrics (ORR, DCR, OS, PFS) combined with a manageable safety profile in heavily pre-treated patients are very encouraging. The progression to a U.S. Phase 1/2a trial further underscores the potential of this asset.

Positives

• Achieved a high Overall Response Rate (ORR) of 40.7% in heavily pre-treated advanced KRAS G12D mutant PDAC patients.
• Demonstrated a strong Disease Control Rate (DCR) of 96.7%, with 91.5% of patients experiencing tumor reduction.
• Reported a promising 92.2% Overall Survival (OS) rate at month four, with median OS not yet reached.
• Showed a median Progression-Free Survival (PFS) of 5.52 months and a 4-month PFS rate of 78.2%.
• Nearly half of the patients (47%) remained on treatment, with some continuing for over a year, indicating sustained benefit.
• The safety profile was manageable, with a low discontinuation rate of 3% due to TRAEs and no TRAE-related deaths.
• VS-7375 is a potential best-in-class, potent, and selective oral KRAS G12D dual ON/OFF inhibitor, addressing a significant unmet medical need as no FDA-approved therapies specifically target KRAS G12D mutations.

Negatives

• Grade 3 treatment-related adverse events (TRAEs) occurred in 30.3% of patients, and a Grade 4 TRAE (neutropenia) occurred in 1.5% of patients.
• Four patients (6.1%) required a dose reduction due to TRAEs.

Risks

• Uncertainties inherent in research and development, including the possibility of negative or unexpected results of clinical trials.
• Risk that the company may not see a return on investment from payments made to GenFleet, or that GenFleet may fail to fully perform under the collaboration agreement.
• Development and commercialization of product candidates may take longer or cost more than planned, potentially due to additional studies or execution decisions.
• Data may not be available when expected, and preliminary/interim data may not be representative of more mature data.
• Uncertainties related to changes in the U.S. presidential administration, including regulatory and policy changes that could adversely affect the business.
• Risks associated with potential reductions to the FDA's workforce, which could lead to disruptions and delays in review and oversight of product candidates.
• Product candidates may not receive regulatory approval, become commercially successful, or result in new treatment options for patients.

Future Outlook

The company plans to continue advancing its Phase 1/2a clinical trial for VS-7375 in the U.S., with potential for global expansion. The trial will evaluate safety and efficacy in advanced KRAS G12D mutant solid tumors, including pancreatic, colorectal, and non-small cell lung cancers, both as monotherapy and in combination regimens. The starting dose for the U.S. Phase 1 study is 400 mg, based on data from the GenFleet study, to accelerate trial progress.

Management Comments

• Dan Paterson, President and Chief Executive Officer of Verastem Oncology, stated, "We are pleased to see that the updated data presented by our partner, GenFleet Therapeutics, continues to demonstrate encouraging clinical responses at the recommended Phase 2 dose, in a heavily pre-treated, often difficult to treat, patient population."
• Paterson added, "These data add to the growing body of evidence supporting the therapeutic potential of KRAS G12D inhibition and importantly provide valuable insights as we continue to advance through our Phase 1/2a trial with VS-7375."

Industry Context

The announcement highlights significant progress in targeting KRAS G12D mutations, which are the most prevalent KRAS mutations in human cancers, particularly in pancreatic (37%), colorectal (12.5%), endometrial (8%), and non-small cell lung (5%) cancers. Currently, there are no FDA-approved therapies specifically targeting KRAS G12D mutations, indicating a substantial unmet medical need. The positive data for VS-7375 positions it as a potential first-in-class treatment in this challenging oncology space, particularly for advanced pancreatic cancer patients who typically have a worse prognosis.

Comparison to Industry Standards

• No therapies are currently approved by the U.S. Food and Drug Administration (FDA) specifically targeting KRAS G12D mutations in cancer, highlighting a significant unmet need that VS-7375 aims to address.
• The reported efficacy data (40.7% ORR, 96.7% DCR, 92.2% 4-month OS) in heavily pre-treated advanced PDAC patients are encouraging, especially given the aggressive nature of pancreatic cancer and the lack of effective targeted treatments for KRAS G12D mutations.
• The manageable safety profile with a low discontinuation rate (3%) due to TRAEs compares favorably to the toxicity profiles often seen with conventional chemotherapy regimens in this patient population.

Stakeholder Impact

• **Shareholders:** Positive clinical data for a lead pipeline asset could significantly increase shareholder value and investor confidence, especially given the large unmet need in KRAS G12D mutant cancers.
• **Patients:** The promising efficacy and manageable safety profile of VS-7375 offer hope for a new, much-needed treatment option for patients with advanced KRAS G12D mutant pancreatic cancer, who currently have limited therapeutic choices.
• **Employees:** Continued positive clinical development supports job security and potential growth opportunities within the company as the pipeline advances.
• **Regulatory Authorities:** The data will be crucial for future discussions with regulatory bodies like the FDA as the company progresses towards potential marketing applications.

Next Steps

• Continue to advance the Phase 1/2a clinical trial for VS-7375 in the U.S.
• Dose escalate across levels where responses were observed in GenFleet's study in the U.S. trial.
• Assess the efficacy and safety of VS-7375 as monotherapy and in combination in patients with advanced solid tumors, including pancreatic, colorectal, and non-small cell lung cancers, in the Phase 2a portion of the U.S. study.
• Potentially expand the U.S. Phase 1/2a study globally.

Key Dates

Recommendation

The updated Phase 1/2 data for VS-7375 in advanced KRAS G12D mutant PDAC are exceptionally strong, demonstrating high ORR (40.7%), DCR (96.7%), and promising OS (92.2% at 4 months) and PFS (5.52 months median) in a heavily pre-treated patient population with a notoriously aggressive cancer and no approved targeted therapies. The manageable safety profile and the progression to a U.S. Phase 1/2a trial further de-risk the asset and highlight its potential as a first-in-class treatment. This data significantly enhances the company's pipeline value and addresses a substantial unmet medical need, making it a compelling investment opportunity.

Keywords

Verastem, VSTM, GenFleet, GFH375, VS-7375, KRAS G12D, Pancreatic Cancer, PDAC, Oncology, Clinical Trial, Phase 1/2, Monotherapy, Biopharmaceutical, Cancer Treatment, Targeted Therapy, RAS/MAPK pathway